Cary J. Claiborne - 18 Mar 2026 Form 3 Insider Report for NeuroSense Therapeutics Ltd. (NRSN)

Role
Director
Signature
/s/ Cary Claiborne
Issuer symbol
NRSN
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 15:36:17 UTC
Previous filing
02 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Claiborne Cary J Director C/O NEUROSENSE THERAPEUTICS LTD., 11 HAMENOFIM STREET, BUILDING B, HERZLIYA, ISRAEL /s/ Cary Claiborne 18 Mar 2026 0001370930

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NRSN Ordinary Shares 48,000 18 Mar 2026 Direct
holding NRSN Ordinary Shares 60,000 18 Mar 2026 Direct F1
holding NRSN Ordinary Shares 99,898 18 Mar 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NRSN Options to Purchase Ordinary Shares 18 Mar 2026 Ordinary Shares 72,000 $1.43 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted shares vest on December 30, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.
F2 These restricted shares vest on January 30, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.
F3 These options are fully vested and exercisable.